Celltrion Reports Positive Data For High-Concentration Adalimumab

Phase III Trials Cover Two Delivery Methods For CT-P17

 
• By Akriti Seth

Celltrion’s phase III study comparing the pharmacokinetics, efficacy and safety profile of its CT-P17 high-concentration adalimumab biosimilar to Humira has yielded positive results. The company is presenting the results at the American College of Rheumatology Convergence 2020.

Needle pen
Celltrion’s trials demonstrated the safety and efficacy of its high-concentration adalimumab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products